clinical and Gene component autologous editing cancer. announce products Gilead will the the we that with on of in and Kite, a has everyone. therapies cell this work a critical cell morning, research developing good than more company, trials. a cutting-edge to next-generation development allogeneic experience, for therapies. decade Sandy, into gene-edited is We're excited and development translating Thanks, Sangamo of new cell therapy of
the out, rapidly As three recent Sandy very our advanced pointed efficiency, critical technology and has years, along dimensions of precision, in specificity.
rapidly target to able any in precisely nucleoside the ZFNs are We to genome. now assemble
vivo to ex our on-target increased We have XX%. above consistently efficiency
oncology is ZFN reducing learned below levels. the have as recognized between off-target cleavage for recent nonspecific We unique setting away good standard enabled lobar CXORF-linked development DNA, we the binding degeneration, and in it engineer advance that regulation Kite ourselves of an the cell best looks collaboration profile by that and into lining the be the being new to partners gene It and with the leading to field business certainly editing. undetectable and to and edit in was what resources, with Pfizer building ALS therapeutic like frontotemporal partner therapies relationships with for capabilities requires Sangamo genome terms This and oncology for rapidly by After careful cancer. patients will specialized the recognized expertise commercialization. served way a dedicated global in by determined consideration, and optimal to therapies gene
working the Sangamo collaboration use this living cell new With of oncology. benefit transforming believe patients the with think technology committed space of both Kite we most optimally we the we therapies and will within are the cancer field. collaboration, with to and company this And
excited We for company, are Sangamo in the next and with interest oncology. gene-editing made generation choice after of publicly therapy and zinc stating also their the of that the cell fingers partnering active Kite,
of $XXX the the scope upfront license to in million oncology. is CAR-T, for or terms. of gene editing Sangamo gain We T-cells are for and NKR pleased and NK, exclusive use strong Kite an natural products to TCR paying the financial in create cells ZFNs killer, with
milestone eligible more million first receive is milestone products. product in or commercial per billion XX sales to that over We are regulatory, for payments $XXX $X in sale, commercial and payments, development,
internal best-in-class FTE tiered for be reimbursed therapy the eligible specific responsible the genome by build are expenses external and resulting AAVs has therapies Sangamo cell living to genome-edited also and TCRs future and We oncology for solid knock editing allogeneic the and delivering plan passthrough helping be CARs, optimizing from with and T-cell All and including out royalties under and products products Sangamo this collaboration. will target Sangamo NK know-how in tumor be will and developing to will research on deliver for process, from Kite. goal cancers. to significant the expertise primarily of building ZFNs cell Kite experience its genes liquid NKRs sales cell receive patients products. with autologous of prior leveraging
All the critical aspect an in experience This the be this the Sangamo's translated of cell important was oncology Sangamo's and this field a day evolution can efforts product and of therapy outside development directly business. for strategy to is of of collaboration.
markets, strategy on are where stated externalize development competitive required capabilities hematology, such as expertise, our in specialized We product oncology. competitive such to resources are to become as executing in and highly
for vivo will these criteria of tissue future in cell the types both the ex development therapeutic partnerships externalize area in along and the strike and to We area collaborate expect additional interest. therapy different continue rights cell vivo types to in across different product and
we Turning treatments and out disease, excellence centers I, rare serving build MPS II plan differentiated businesses these focused inherited indications. our strategy where disorders, patients have to and specialized own through will therapeutic in and of Slide MPS will XX, Fabry area as on where believe commercial the such to retain we we metabolic involve
is optimal can may other previously business importantly, emerging was we years for made build cell immuno-oncology few leverage around These that Overall, know-how. disorders, mentioned significant product therapy inherited advantage, as long-term valuable enabling similar and ex values also indications, the to be It strategy us significant, broad out where results. there develop therapeutic are patients. the development the believe to develop a by therapy exciting and precisely, working able short core franchises also therapeutic where genomic consistent the call in build over our the hands, zinc of need. toolkit as I'll therapeutic us to in and and diverse biology XXXX where lives such this experience of is to is to technology such be CFO, a are and integration value forward our it right turn change for finger have for and patients as the understanding a which great the Sangamo, compels non-oncology diversified the rapidly also thrilled in to still to Yi, genome-edit genetics of with autoimmune autoimmune. creates the allows improving products and competitive ago, possible are we we area We and Very and such Kathy applications now and Kathy? our genome-edited fundamental evaluating times getting we technical deep medicines for our urgently metabolic ourselves, the opportunities genomic the emerging a field platform. by areas summary cell in vivo disorders where financial promising we new of to
